Comprehensive review of histone lactylation: Structure, function, and therapeutic targets

被引:23
作者
Xu, Kaiwen [1 ]
Zhang, Keyi [1 ]
Wang, Yanshuang [2 ]
Gu, Yue [1 ]
机构
[1] Anhui Med Univ, Inst Clin Pharmacol, Key Lab Antiinflammatory & Immune Med, Minist Educ, 81 Meishan Rd, Hefei 230032, Peoples R China
[2] Hainan Med Univ, Sch Trop Med, NHC Key Lab Trop Dis Control, Lab Med, Haikou 571199, Peoples R China
关键词
Histone lactylation; Acylation modifications; Metabolic pathways; Epigenetic regulation; Drug targets; METABOLIC-REGULATION; GENE-EXPRESSION; LACTATE-DEHYDROGENASE; P300/CBP INHIBITOR; IDENTIFICATION; TRANSCRIPTION; TRANSPORTER; ACTIVATION; DISCOVERY;
D O I
10.1016/j.bcp.2024.116331
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Histone lysine lactylation (Kla) has emerged as a distinct epigenetic modification that differs markedly from established acylation modifications through the unique addition of a lactyl group to a lysine residue. Such modifications not only alter nucleosome structure but also significantly impact chromatin dynamics and gene expression, thus playing a crucial role in cellular metabolism, inflammatory responses, and embryonic development. The association of histone Kla with various metabolic processes, particularly glycolysis and glutamine metabolism, underscores its pivotal role in metabolic reprogramming, including in cancerous tissues, where it contributes to tumorigenesis, immune evasion, and angiogenesis. In addition, histone Kla is involved in the pathogenesis of various diseases, particularly several cancers and neurodegenerative diseases. The identification of histone Kla opens new avenues for therapeutic interventions targeting specific Kla sites. In this review, we summarize the differences between histone Kla modifications and other acylation modifications, discuss the mechanisms and roles of histone Kla in disease, and conclude by describing existing drugs and potential targets. This study provides new insights into the mechanisms linking histone Kla to diseases and into the discovery of new drugs and targets.
引用
收藏
页数:11
相关论文
共 91 条
[1]   Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment [J].
Barron, Carly C. ;
Bilan, Philip J. ;
Tsakiridis, Theodoros ;
Tsiani, Evangelia .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2016, 65 (02) :124-139
[2]   Virtual Ligand Screening of the p300/CBP Histone Acetyltransferase: Identification of a Selective Small Molecule Inhibitor [J].
Bowers, Erin M. ;
Yan, Gai ;
Mukherjee, Chandrani ;
Orry, Andrew ;
Wang, Ling ;
Holbert, Marc A. ;
Crump, Nicholas T. ;
Hazzalin, Catherine A. ;
Liszczak, Glen ;
Yuan, Hua ;
Larocca, Cecilia ;
Saldanha, S. Adrian ;
Abagyan, Ruben ;
Sun, Yan ;
Meyers, David J. ;
Marmorstein, Ronen ;
Mahadevan, Louis C. ;
Alani, Rhoda M. ;
Cole, Philip A. .
CHEMISTRY & BIOLOGY, 2010, 17 (05) :471-482
[3]   Chemical phylogenetics of histone deacetylases [J].
Bradner, James E. ;
West, Nathan ;
Grachan, Melissa L. ;
Greenberg, Edward F. ;
Haggarty, Stephen J. ;
Warnow, Tandy ;
Mazitschek, Ralph .
NATURE CHEMICAL BIOLOGY, 2010, 6 (03) :238-243
[4]   Current Trends in Sirtuin Activator and Inhibitor Development [J].
Bursch, Karina L. ;
Goetz, Christopher J. ;
Smith, Brian C. .
MOLECULES, 2024, 29 (05)
[5]   Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents [J].
Chen, Qingjuan ;
Yang, Binhui ;
Liu, Xiaochen ;
Zhang, Xu D. ;
Zhang, Lirong ;
Liu, Tao .
THERANOSTICS, 2022, 12 (11) :4935-4948
[6]   Identification of a novel GLUT1 inhibitor with in vitro and in vivo anti-tumor activity [J].
Chen, Xiaotong ;
Zhao, Yunshuo ;
He, Chuanjie ;
Gao, Guanfei ;
Li, Jiao ;
Qiu, Lu ;
Wang, Xiaoxi ;
Gao, Yanfeng ;
Qi, Yuanming ;
Sun, Kai ;
Du, Jiangfeng .
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2022, 216 :768-778
[7]   Posttranslational lysine 2-hydroxyisobutyrylation of human sperm tail proteins affects motility [J].
Cheng, Yi-min ;
Peng, Zhen ;
Chen, Hou-yang ;
Pan, Ting-ting ;
Hu, Xiao-nian ;
Wang, Fang ;
Luo, Tao .
HUMAN REPRODUCTION, 2020, 35 (03) :494-503
[8]   Sirtuin activators and inhibitors: Promises, achievements, and challenges [J].
Dai, Han ;
Sinclair, David A. ;
Ellis, James L. ;
Steegborn, Clemens .
PHARMACOLOGY & THERAPEUTICS, 2018, 188 :140-154
[9]   Lactate promotes myogenesis via activating H3K9 lactylation-dependent up-regulation of Neu2 expression [J].
Dai, Weilong ;
Wu, Gang ;
Liu, Ke ;
Chen, Qianqian ;
Tao, Jingli ;
Liu, Honglin ;
Shen, Ming .
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2023, 14 (06) :2851-2865
[10]   EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified Neuroblastoma [J].
Durbin, Adam D. ;
Wang, Tingjian ;
Wimalasena, Virangika K. ;
Zimmerman, Mark W. ;
Li, Deyao ;
Dharia, Neekesh, V ;
Mariani, Luca ;
Shendy, Noha A. M. ;
Nance, Stephanie ;
Patel, Anand G. ;
Shao, Ying ;
Mundada, Maya ;
Maxham, Lily ;
Park, Paul M. C. ;
Sigua, Logan H. ;
Morita, Ken ;
Conway, Amy Saur ;
Robichaud, Amanda L. ;
Perez-Atayde, Antonio R. ;
Bikowitz, Melissa J. ;
Quinn, Taylor R. ;
Wiest, Olaf ;
Easton, John ;
Schonbrunn, Ernst ;
Bulyk, Martha L. ;
Abraham, Brian J. ;
Stegmaier, Kimberly ;
Look, A. Thomas ;
Qi, Jun .
CANCER DISCOVERY, 2022, 12 (03) :730-751